MEDPHealthcare · Diagnostics & ResearchThe 14 Wall Street analysts covering Medpace Holdings, Inc. hold a median 12-month price target of $673 — -0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 28 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Medpace Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (97): The business earns solid, repeatable profits on what it owns.
Accruals (64): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MEDP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.7% from it.
Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | BMO Capital | Maintains | Market Perform | $600 → $670 |
| 23 Oct 2026 | Barclays | Maintains | Equal-Weight | $625 → $675 |
| 23 Oct 2026 | TD Cowen | Maintains | Hold | $492 → $673 |
| 23 Oct 2026 | Truist Securities | Maintains | Hold | $609 → $633 |
| 23 Oct 2026 | UBS | Maintains | Neutral | $673 → $700 |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | $600 → $625 |
| 7 Oct 2026 | Mizuho | Maintains | Outperform | $665 → $700 |
| 7 Oct 2026 | Mizuho | Maintains | Outperform | — |
| 30 Sept 2026 | UBS | Upgrade | Neutral | $405 → $673 |
| 30 Sept 2026 | UBS | Upgrade | Neutral | — |
| 24 July 2026 | Baird | Maintains | Neutral | $547 → $624 |
| 24 July 2026 | Baird | Maintains | Neutral | — |
| 24 July 2026 | BMO Capital | Maintains | Market Perform | — |
| 24 July 2026 | BMO Capital | Maintains | Market Perform | $400 → $600 |
| 24 July 2026 | Mizuho | Maintains | Outperform | — |
| 24 July 2026 | Mizuho | Maintains | Outperform | $586 → $665 |
| 24 July 2026 | RBC Capital | Maintains | Outperform | $484 → $692 |
| 24 July 2026 | RBC Capital | Maintains | Outperform | — |
| 24 July 2026 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MEDP appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Medpace Holdings, Inc. returned +15.9% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 18% of US stocks
Cheaper than 3% of US stocks
Cheaper than 9% of US stocks
Higher than 49% of US stocks
Higher than 62% of US stocks
Higher than 32% of US stocks
Higher than 82% of US stocks
Higher than 81% of US stocks
Higher than 97% of US stocks
Higher than 98% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medpace Holdings, Inc. has a market value of $19.4B and an enterprise value of $18.8B.
Revenue in the twelve months to 30 June 2026: $2.8B. The latest quarter grew 8.5% year on year.
Net income over the same four quarters: $491.5M, a 17.7% net margin.
Diluted earnings per share, trailing twelve months: $17.06.
Free cash flow in the twelve months to 30 June 2026: $706.7M.
Medpace Holdings, Inc. spent $299.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 37.4×; forward P/E: 34.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Medpace Holdings, Inc. employs 6,600 people — $422K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medpace Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research item notes that Medpace Holdings (MEDP) has reached a 52-week high and says it examines the company’s fundamentals for clues about whether further gains may be possible.
Why it matters — MEDP watchers may find the article’s focus on the company’s fundamentals relevant when assessing the stock’s recent high.
Zacks Investment Research says Medpace has solid growth attributes that could help it outperform the market, and the headline presents three reasons supporting that view.
Why it matters — The item offers a growth-oriented perspective on Medpace for investors following the company.
Medpace (MEDP) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The source says this might drive the stock higher in the near term.
Why it matters — MEDP watchers may note the upgrade as a sign of increased optimism about the company’s earnings prospects.
Zacks Investment Research published an article titled “Here's Why Medpace (MEDP) is a Strong Growth Stock,” introducing the Zacks Style Scores as a way to identify stocks.
Why it matters — The article frames Medpace as a strong growth stock and points readers to the Zacks Style Scores, but the excerpt provides no company-specific rationale.
Seeking Alpha downgraded Medpace from Buy to Hold, citing decelerating growth metrics and underwhelming forward guidance. Q3 2026 net new business awards grew 10.6%, down from 28.2% in Q2, while revenue rose 8.5% to $716 million, compared with 17.2% growth in the prior quarter.
Why it matters — The slower award and revenue growth rates may concern MEDP watchers assessing contract momentum and the company’s growth outlook.
The 14 Wall Street analysts covering Medpace Holdings, Inc. have a median 12-month price target of $673, with estimates ranging from $370 to $730. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Medpace Holdings, Inc., 2 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Medpace Holdings, Inc. 95 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Medpace Holdings, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies -0.7% from the last close, and Ticker Nerd's factor model ranks Medpace Holdings, Inc. 95 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medpace Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $370 to $730 over the next 12 months.
Medpace Holdings, Inc. returned +15.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?". A Zacks Investment Research item notes that Medpace Holdings (MEDP) has reached a 52-week high and says it examines the company’s fundamentals for clues about whether further gains may be possible.
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.
CEO Dr. August James Troendle M.D. · 6,600 employees · United States · https://www.medpace.com
